Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Annals of the Rheumatic Diseases

• Publication date

  2011-10-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/ard.2011.153601PMID 22021864
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades.

  2011cited by this paper
• Wegener’s Granulomatosis Strictly and Persistently Localized to One Organ Is Rare: Assessment of 16 Patients from the French Vasculitis Study Group Database

  2011cited by this paper
• The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis.

  2010cited by this paper
• Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage?

  2010cited by this paper
• Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

  2010cited by this paper
• Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

  2010cited by this paper
• Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis.

  2009cited by this paper
• Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis

  2009cited by this paper
• B‐cell depletion with rituximab for refractory head and neck Wegener’s granulomatosis: a cohort study

  2009cited by this paper
• A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

  2009cited by this paper
• Improved outcome in Wegener’s granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts

  2009cited by this paper
• Modification and validation of the Birmingham Vasculitis Activity Score (version 3)

  2008cited by this paper
• Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients.

  2008cited by this paper
• Sclerosing Wegener’s granulomatosis in the orbit

  2008cited by this paper
• Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease.

  2008cited by this paper
• Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement.

  2008cited by this paper
• Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations.

  2008cited by this paper
• Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients.

  2007cited by this paper
• Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.

  2006cited by this paper
• EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis

  2006cited by this paper
• Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.

  2006cited by this paper
• Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.

  2006cited by this paper
• Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.

  2005cited by this paper
• Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations

  2005cited by this paper
• Anti‐CD20 therapy of treatment‐resistant Wegener's granulomatosis: favourable but temporary response

  2005cited by this paper
• Nine patients with anti‐neutrophil cytoplasmic antibody‐positive vasculitis successfully treated with rituximab

  2005cited by this paper
• Wegener's Granulomatosis of the Orbit: A Clinicopathological Study of 15 Patients

  2002cited by this paper
• Development and validation of a disease extent index for Wegener's granulomatosis.

  2001cited by this paper
• The clinical and pathologic constellation of Wegener granulomatosis of the orbit.

  1997cited by this paper
• Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.

  1997cited by this paper
• Nomenclature of systemic vasculitides. Proposal of an international consensus conference.

  1994cited by this paper
• Diagnostic value and limitations of orbital biopsy in Wegener's granulomatosis.

  1992cited by this paper
• Diagnostic Value and Limitations of Orbital Biopsy in Wegener's Granutomatosis

  1992cited by this paper
• Wegener Granulomatosis: An Analysis of 158 Patients

  1992cited by this paper
• Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.

  1983cited by this paper

• Cytomegalovirus infection in patients with rheumatic disorders under rituximab treatment: a scoping review

  2026influential citation
• Management of antineutrophil cytoplasmic antibody vasculitis-associated orbital inflammatory disease: A systematic literature review.

  2025cites this paper
• Central nervous system involvement in ANCA-associated vasculitis

  2025cites this paper
• Clinician views concerning the prevalence and impact of granulomas on the diagnosis, management, and outcomes of ANCA-associated vasculitis.

  2025cites this paper
• Immunosuppression and Surgery-Free Interval in Granulomatosis With Polyangiitis Airway Stenosis.

  2025cites this paper
• Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden

  2025cites this paper
• Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden

  2025cites this paper
• Medical, Endoscopic, and Surgical Strategies in the Management of Subglottic Stenosis in Granulomatosis With Polyangiitis: A Case Series.

  2025cites this paper
• Abatacept and multiple therapeutic bronchoscopies as salvage therapy for refractory tracheobronchial inflammation and stenosis in GPA

  2025cites this paper
• Treatment options for necrotizing scleritis in rheumatoid arthritis patients

  2024cites this paper
• Hyperkeratotisch‐krustöse Plaques an den Beinen, Arthralgien und chronische Otitis bei einem 11‐jährigen Mädchen

  2024cites this paper
• Two Decades Rituximab Therapy in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis.

  2024cites this paper
• Hyperkeratotic‐encrusted plaques on the legs, arthralgias, and chronic otitis in a 11‐year‐old girl

  2024cites this paper
• Headaches and Vasculitis.

  2024cites this paper
• Sialadenitis in Antineutrophil Cytoplasmic Antibodies Vasculitis.

  2024cites this paper
• Induction failure in granulomatosis with polyangiitis: a nationwide case-control study of risk factors and outcomes.

  2023cites this paper
• Recent advances in the treatment strategy for AAV improved outcomes with intensive GC tapering

  2023cites this paper
• ANCA-associated vasculitis: overview and practical issues of diagnosis and therapy from a European perspective

  2023cites this paper
• Anti-neutrophil cytoplasmic antibody associated vasculitis following rituximab: Outcomes of 50 patients in a tertiary single centre

  2023influential citation
• Intracranial granuloma in a patient with granulomatosis with polyangiitis under rituximab maintenance: A case report

  2023cites this paper
• Combination Treatment of Locoregionally Aggressive Granulomatosis with Polyangiitis and Cranial Base Infiltration

  2023cites this paper
• Identification of Covariates Modulating B‐Cell Repopulation Kinetics in Subjects Receiving Rituximab Treatment

  2023cites this paper
• Rituximab resistance at 3 months of induction therapy in newly diagnosed or relapsing ANCA associated vasculitis: a French multicentre study.

  2023cites this paper
• Role of systemic immunosuppression on subglottic stenosis in granulomatosis with polyangiitis: Analysis of a single-centre cohort.

  2023cites this paper
• Systemic and Local Medical or Surgical Therapies for Ear, Nose and/or Throat Manifestations in ANCA-Associated Vasculitis: A Systematic Literature Review

  2023influential citation
• Response to Treatment With Tofacitinib in 11 Patients With Refractory Granulomatosis With Polyangiitis

  2023cites this paper
• A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol

  2023cites this paper
• ANCA‐associated refractory vasculitis with multiple systemic involvement: A rare case report

  2023cites this paper
• Analysis of treatment outcomes in patients with antineutrophil cytoplasmic antibody-associated vasculitis on rituximab therapy

  2022influential citation
• The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review

  2022cites this paper
• Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis

  2022cites this paper
• Antineutrophil Cytoplasmic Antibody–Associated Orbital Inflammatory Syndrome Without Extraocular Manifestations

  2022cites this paper
• Updates in ANCA-associated vasculitis

  2022cites this paper
• Granulomatosis with Polyangiitis-GPA (Wegener’s Granulomatosis)

  2021cites this paper
• Granulomatosis with Polyangiitis: Experience of 42 Patients from a Single-Center, Tertiary Care Hospital in Mumbai

  2021cites this paper
• Rituximab plus methotrexate combination as a salvage therapy in persistently active granulomatosis with polyangiitis.

  2021cites this paper
• Ear, nose, and throat in ANCA-associated vasculitis: a comprehensive review

  2021cites this paper
• Localised Versus Systemic Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Registry.

  2021cites this paper
• Rituximab for treatment of non-infectious and non-malignant orbital inflammatory disease

  2021cites this paper
• Lupus nephritis and ANCA-associated vasculitis: towards precision medicine?

  2021cites this paper
• The clinical efficacy of Rituximab administration in autoimmunity disorders, primary immunodeficiency diseases and malignancies.

  2021cites this paper
• Pituitary involvement in a case of granulomatosis with polyangiitis: case report and literature review

  2021cites this paper
• und andere primäre systemische Vaskulitiden (engl. granulomatosis with polyangiitis)

  2021cites this paper
• Sustained Remission of Granulomatosis With Polyangiitis After Discontinuation of Glucocorticoids and Immunosuppressant Therapy: Data From the French Vasculitis Study Group Registry

  2020cites this paper
• Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis

  2020cites this paper
• Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report

  2020cites this paper
• Vascular Disorders of the Lung

  2020cites this paper
• Successful Treatment with Rituximab for Granulomatosis with Polyangiitis and Multiple Cranial Neuropathies

  2020cites this paper
• Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review

  2020cites this paper
• Lung involvement in ANCA-associated vasculitis.

  2020cites this paper
• ANCA-ASSOCIATED VASCULITIDES: RECOMMENDATIONS OF THE FRENCH VASCULITIS STUDY GROUP ON THE USE OF IMMUNOSUPPRESSANTS AND BIOTHERAPIES FOR REMISSION INDUCTION AND MAINTENANCE.

  2020cites this paper
• Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis.

  2020cites this paper
• Is Rituximab “The Wonder Drug” for Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis?

  2019cites this paper
• Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients

  2019cites this paper
• Targeted immunotherapy strategies in ANCA-associated vasculitis.

  2019cites this paper
• Relapsing granulomatosis with polyangiitis provoked by trauma

  2019cites this paper
• Rituximab as an effective and probably safe treatment for granulomatosis with polyangiitis (Wegener's Granulomatosis).

  2019cites this paper
• Ocular involvement in granulomatosis with polyangiitis: A single-center cohort study on 63 patients.

  2019cites this paper
• Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients.

  2019cites this paper
• Treatment Strategies in ANCA-Associated Vasculitis

  2019cites this paper
• Stratégies d’immunothérapie ciblée au cours des vascularites associées aux ANCA

  2019cites this paper
• Clinical and histopathological findings of patients with orbital granulomatosis with polyangiitis cases refractory to rituximab.

  2019cites this paper
• Granulomatosis with Polyangiitis

  2019cites this paper
• Rituximab Versus Cyclophosphamide for Central Nervous System Involvement of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Case Series.

  2019cites this paper
• Disease heterogeneity in antineutrophil cytoplasmic antibody-associated vasculitis: implications for therapeutic approaches.

  2019cites this paper
• Vaskulitis-Mimics

  2019cites this paper
• Successful reconstruction of an ocular defect resulting from granulomatosis with polyangiitis, following treatment with rituximab

  2018cites this paper
• B cell therapy in ANCA-associated vasculitis: current and emerging treatment options

  2018cites this paper
• Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial.

  2018cites this paper
• Clinical manifestations of granulomatosis with polyangiitis: key considerations and major features

  2018cites this paper
• Unmet Needs in the Pathogenesis and Treatment of Vasculitides

  2018cites this paper
• Long-term disease control in granulomatosis with polyangiitis: is low-dose rituximab the cure?

  2018cites this paper
• Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies

  2018cites this paper
• Anti-neutrophil Cytoplasmic Autoantibodies Associated Vasculitis - Clinical Profile and Outcomes

  2018cites this paper
• Peripheral Ulcerative Keratitis Associated with Granulomatosis with Polyangiitis Emerging Despite Cyclophosphamide, Successfully Treated with Rituximab

  2018cites this paper
• Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)

  2018cites this paper
• Successful rituximab treatment of granulomatosis with polyangiitis with cranial neuropathies

  2018cites this paper
• Granulomatosis with Polyangiitis (GPA) Mimicking Tuberculosis.

  2017cites this paper
• S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden

  2017influential citation
• Pharmacogenetics of rituximab in anca-associated vasculitis

  2017cites this paper
• Pulmonary Involvement in Systemic Vasculitis

  2017cites this paper
• Actualités thérapeutiques de la granulomatose avec polyangéite (Wegener) et de la polyangéite microscopique

  2017cites this paper
• Pachymeningitis and cerebral granuloma in granulomatosis with polyangiitis: is rituximab a promising treatment option?

  2017cites this paper
• Vasculitis for the internist: focus on ANCA-associated vasculitis

  2017cites this paper
• S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden

  2017cites this paper
• Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis

  2017cites this paper
• Healing of leg ulcers associated with granulomatosis with polyangiitis (Wegener granulomatosis) after rituximab therapy.

  2017cites this paper
• Granulomatosis with polyangiitis presenting as a pituitary lesion.

  2017cites this paper
• B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients

  2017cites this paper
• M2 macrophage is the predominant phenotype in airways inflammatory lesions in patients with granulomatosis with polyangiitis

  2017cites this paper
• Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: A new overlap syndrome.

  2017cites this paper
• B-cell-targeted therapy in systemic vasculitis

  2016cites this paper
• Rituximab as maintenance therapy for ANCA associated vasculitis: how, when and why?

  2016cites this paper
• The efficacy of submucosal corticosteroid injection and dilatation in subglottic stenosis of different aetiology

  2016cites this paper
• Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: A report of 6 cases.

  2016cites this paper
• Good response to rituximab in a patient with granulomatosis with polyangiitis and pulmonary, renal manifestations and ophthalmoplegia.

  2016cites this paper
• Granulomatosis with Polyangiitis (GPA)

  2016cites this paper
• Outcome of Localized Granulomatosis with Polyangiitis: A Case Study

  2016cites this paper
• Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab

  2016cites this paper
• Granulomatosis with Polyangiitis of Sinonasal Tract

  2016cites this paper